Medical management of myelodysplastic syndrome (MDS) remains challenging, particularly in advanced stages where the risk of developing acute leukemia is very high and the prospect of survival is generally poor. Over the past decade, epigenetic changes such as alterations in DNA methylation and histone modifications have been well described in MDS and are now recognized as targets of therapy (epigenetic therapy). The aim of epigenetic therapy is to reverse epigenetic changes and reactivate important genes, thereby modifying the malignant phenotype and inducing the clearance of the malignant clone via various mechanisms. Epigenetic-modifying agents may also have mechanisms of anticancer action unrelated to gene reactivation. The hypomethylating agents azacitidine and decitabine induce clinically meaningful remissions or improvements in 30% to 60% of patients with this disease, and both agents have been approved in the United States for the treatment of advanced and/or symptomatic MDS. Histone deacetylase inhibitors belong to another class of epigenetic-modifying agents that also have clinical activity in MDS. They are currently being combined with hypomethylating agents. Among other available therapeutic options, allogeneic stem cell transplantation is the only curative approach for MDS but is also characterized by significant morbidities and mortality. We review epigenetic therapy and other therapeutic approaches for patients with advanced MDS.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Hanahan D, Weinberg RA. The hallmarks of cancer.Cell. 2000;100:57–70.
Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer.Nat Rev Genet. 2002;3:415–428.
Bird A. DNA methylation patterns and epigenetic memory.Genes Dev. 2002;16:6–21.
Strahl BD, Allis CD. The language of covalent histone modifications.Nature. 2000;403:41–45.
Jenuwein T, Allis CD. Translating the histone code.Science. 2001;293:1074–1080.
Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. JClin Oncol. 2005;23:3971–3993.
Claus R, Lubbert M. Epigenetic targets in hematopoietic malignancies.Oncogene. 2003;22:6489–6496.
Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes.Blood. 1997;89:2079–2088.
Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation.N Engl J Med. 2003;349:2042–2054.
Robertson KD. DNA methylation, methyltransferases, and cancer.Oncogene. 2001;20:3139–3155.
Li E. Chromatin modification and epigenetic reprogramming in mammalian development.Nat Rev Genet. 2002;3:662–673.
Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex.Nature. 1998;393:386–389.
Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylationofp15 INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia.Leukemia. 2003;17:1813–1819.
Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia.Cancer Res. 1999;59:3730–3740.
Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies.Blood. 2004;103:1635–1640.
Uchida T, Kinoshita T, Nagai H, et al. Hypermethylation of thep15 INK4B gene in myelodysplastic syndromes.Blood. 1997;90:1403–1409.
Voso MT, Scardocci A, Guidi F, et al. Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes.Blood. 2004;103:698–700.
Brakensiek K, Länger F, Schlegelberger B, Kreipe H, Lehmann U. Hypermethylation of the suppressor of cytokine signalling-1(SOCS-1) in myelodysplastic syndrome.Br J Haematol. 2005;130:209–217.
Johan MF, Bowen DT, Frew ME, Goodeve AC, Reilly JT. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia.Br J Haematol. 2005;129:60–65.
Shen L, Kantarjian H, Saba H, et al. CpG island methylation is a poor prognostic factor in myelodysplastic syndrome patients and is reversed by decitabine therapy: results of a phase III randomized study [abstract]. Blood 2005;106. Abstract 790.
Issa JP. Decitabine.Curr Opin Oncol. 2003;15:446–451.
Cihák A, Vesely J. Prolongation of the lag period preceding the enhancement of thymidine and thymidylate kinase activity in regenerating rat liver by 5-azacytidine.Biochem Pharmacol. 1972;21:3257–3265.
Cih ák A, Vesely J, Skoda J. Azapyrimidine nucleosides: metabolism and inhibitory mechanisms.Adv Enzyme Regul. 1985;24:335–354.
Adams RL, Burdon RH. DNA methylation in eukaryotes.CRC Crit Rev Biochem. 1982;13:349–384.
Creusot F, Acs G, Christman JK. Inhibition of DNA methyltrans-ferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. JBiol Chem. 1982;257:2041–2048.
Li LH, Olin EJ, Fraser TJ, Bhuyan BK. Phase specificity of 5-azacytidine against mammalian cells in tissue culture.Cancer Res. 1970;30:2770–2775.
Li LH, Olin EJ, Buskirk HH, Reineke LM. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia.Cancer Res. 1970;30:2760–2769.
Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.Oncogene. 2002;21:5483–5495.
Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation.Cell. 1980;20:85–93.
Aparicio A, Weber JS. Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors.Curr Opin Investig Drugs. 2002;3:627–633.
Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia.Pharmacol Ther. 1985;30:277–286.
Rivard GE, Momparler RL, Demers J, et al. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia.Leuk Res. 1981;5:453–462.
Petti MC, Mandelli F, Zagonel V, et al. Pilot study of 5-aza-2-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results.Leukemia. 1993;7(Suppl 1):36–41.
Kantarjian HM, O’Brien SM, Estey E, et al. Decitabine studies in chronic and acute myelogenous leukemia.Leukemia. 1997;11(Suppl 1):S35-S36.
Willemze R, Suciu S, Archimbaud E, et al. A randomized phase II study on the effects of 5-aza-2-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).Leukemia. 1997;11(Suppl 1):S24-S27.
Zagonel V, Lo Re G, Marotta G, et al. 5-Aza-2-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes.Leukemia. 1993;7(Suppl 1):30–35.
Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.Leukemia. 1997;11:1–5.
Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. JClin Oncol. 2000;18:956–962.
Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.Cancer. 2006;106:1794–1803.
Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia.Blood. 2007;109:52–57.
Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.Blood. 2006;108:419–425.
Shnider BI, Baig M, Colsky J. A phase I study of 5-azacytidine (NSC-102816). JClin Pharmacol. 1976;16:205–212.
Levi JA, Wiernik PH. A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlympho-cytic leukemia.Cancer. 1976;38:36–41.
Vogler WR, Winton EF, Gordon DS, Raney MR, Go B, Meyer L. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.Blood. 1984;63:1039–1045.
Bellet RE, Mastrangelo MJ, Engstrom PF, Strawitz JG, Weiss AJ, Yarbro JW. Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816).Cancer Chemother Rep. 1974;58:217–222.
Glover AB, Leyland-Jones BR, Chun HG, Davies B, Hoth DF. Azacitidine: 10 years later.Cancer Treat Rep. 1987;71:737–746.
Von Hoff DD, Slavik M, Muggia FM. 5-Azacytidine: a new anti-cancer drug with effectiveness in acute myelogenous leukemia.Ann Intern Med. 1976;85:237–245.
Steuber CP, Holbrook T, Camitta B, Land VJ, Sexauer C, Krischer J. Toxicity trials of amsacrine (AMSA) and etopo-side +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study.Invest New Drugs. 1991;9:181–184.
Ley TJ, DeSimone J, Anagnou NP, et al. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ tha-lassemia.N EnglJ Med. 1982;307:1469–1475.
Charache S, Dover G, Smith K, Talbot CC Jr, Moyer M, Boyer S. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with non-random hypomethylation of DNA around the ã-ä-β-globin gene complex.Proc NatlAcad Sci USA. 1983;80:4842–4846.
Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.Leukemia. 1993;7(Suppl 1):21–29.
Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia GroupB. J Clin Oncol. 2002;20:2429–2440.
Kaminskas E, Farrell A, Abraham S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.Clin Cancer Res. 2005;11:3604–3608.
Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. JClin Oncol. 2006;24:3895–3903.
Borthakur G, Ravandi-Kashani F, Cortes J, et al. Decitabine induces responses in patients with myelodysplastic syndrome (MDS) after failure of azacitidine therapy [abstract].Blood 2006;108. Abstract 518.
Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment.Blood. 2002;100:2957–2964.
Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltrans-ferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.Cancer Res. 2006;66:6361–6369.
Oki Y, Jelinek J, Kantarjian H, Issa JP. Hypomethylation induction and molecular response after decitabine therapy in chronic myelomonocytic leukemia (CMML) [abstract].Blood 2006;108. Abstract 2322.
Goffin J, Eisenhauer E. DNA methyltransferase inhibitors: state of the art.Ann Oncol. 2002;13:1699–1716.
Wilhelm M, O’Brien S, Rios MB, et al. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase.Leuk Lymphoma. 1999;34:511–518.
Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. JMol Biol. 2002;321:591–599.
Yoo CB, Cheng JC, Jones PA. Zebularine: a new drug for epigenetic therapy.Biochem Soc Trans. 2004;32:910–912.
Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain.Cell. 1997;90:595–606.
Watamoto K, Towatari M, Ozawa Y, et al. Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation.Oncogene. 2003;22:9176–9184.
Imhof A, Yang XJ, Ogryzko VV, Nakatani Y, Wolffe AP, Ge H. Acetylation of general transcription factors by histone acetyltrans-ferases.Curr Biol. 1997;7:689–692.
Friedman AD. Leukemogenesis by CBF oncoproteins.Leukemia. 1999;13:1932–1942.
Rodriquez M, Aquino M, Bruno I, De Martino G, Taddei M, Gomez-Paloma L. Chemistry and biology of chromatin remodeling agents: state of art and future perspectives of HDAC inhibitors.Curr Med Chem. 2006;13:1119–1139.
Sowa Y, Orita T, Minamikawa S, et al. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites.Biochem Biophys Res Commun. 1997;241:142–150.
Kim S, Kang JK, Kim YK, et al. Histone deacetylase inhibitor apicidin induces cyclin E expression through Sp1 sites.Biochem Biophys Res Commun. 2006;342:1168–1173.
Alao JP, Lam EW, Ali S, et al. Histone deacetylase inhibitor trichostatin A represses estrogen receptor β-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.Clin Cancer Res. 2004;10:8094–8104.
Alao JP, Stavropoulou AV, Lam EW, Coombes RC, Vigushin DM. Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells.Mol Cancer. 2006;5:8.
Li H, Wu X. Histone deacetylase inhibitor, trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells.Biochem Biophys Res Commun. 2004;324:860–867.
Zhang HS, Gavin M, Dahiya A, et al. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF.Cell. 2000;101:79–89.
Brooks CL, Gu W. Ubiquitination, phosphorylation and acetyla-tion: the molecular basis for p53 regulation.Curr Opin Cell Biol. 2003;15:164–171.
Fuino L, Bali P, Wittmann S, et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.Mol Cancer Ther. 2003;2:971–984.
Nimmanapalli R, Fuino L, Bali P, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.Cancer. Res. 2003;63:5126–5135.
Gaymes TJ, Padua RA, Pla M, et al. Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?Mol Cancer Res 2006;4:563–573.
Ungerstedt JS, Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.Proc NatlAcad Sci USA. 2005;102:673–678.
Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?Cancer Cell 2003;4:13–18.
Insinga A, Minucci S, Pelicci PG. Mechanisms of selective anticancer action of histone deacetylase inhibitors.Cell Cycle. 2005;4:741–743.
Dowdy SC, Jiang S, Zhou XC, et al. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and micro-tubule stabilization in papillary serous endometrial cancer cells.Mol Cancer Ther. 2006;5:2767–2776.
Friedmann I, Atmaca A, Chow KU, Jager E,Weidmann E. Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. JChemother. 2006;18:415–420.
Kim GD, Choi YH, Dimtchev A, Jeong SJ, Dritschilo A, Jung M. Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase. JBiol Chem. 1999;274:31127–31130.
Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.Nat Genet. 1999;21:103–107.
Bai J, Demirjian A, Sui J, Marasco W, Callery MP Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells.Biochem Biophys Res Commun. 2006;348:1245–1253.
Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodys-plastic syndromes with valproic acid alone or in combination withall-trans retinoic acid.Blood. 2004;104:1266–1269.
Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2-deoxycytidine with valproic acid in patients with leukemia.Blood. 2006;108:3271–3279.
Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia.Blood. 2002;100:1997–2004.
Solomon SR, Savani BN, Childs R, et al. Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome.Biol Blood Marrow Transplant. 2005;11:619–626.
Kuendgen A, Strupp C, Aivado M, et al. Myelodysplastic syndromes in patients younger than age 50. JClin Oncol. 2006;24:5358–5365.
Cermak J, Vitek A, Michalova K. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation.Leuk Res. 2004;28:551–557.
Maloney DG, Sandmaier BM, Mackinnon S, Shizuru JA. Non-myeloablative tansplantation.Hematology Am Soc Hematol Educ Program 2002:392–421.
Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.Blood. 2006;108:836–846.
De Witte T, Van Biezen A, Hermans J, et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS: Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation.Blood. 1997;90:3853–3857.
Kantarjian H, Beran M, Cortes J, et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.Cancer. 2006;106:1099–1109.
Beran M, Estey E, O’Brien S, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. JClin Oncol. 1999;17:2819–2830.
Miller KB, Kim K, Morrison FS, et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study.Ann Hematol. 1992;65:162–168.
Zwierzina H, Suciu S, Loeffler-Ragg J, et al. Low-dose cytosine ara-binoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.Leukemia. 2005;19:1929–1933.
Sekeres MA, List A. Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?Curr Hematol Rep 2005;4:182–185.
Kurzrock R, Albitar M, Cortes JE, et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. JClin Oncol. 2004;22:1287–1292.
Kurzrock R, Kantarjian HM, Cortes JE, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.Blood. 2003;102:4527–4534.
Faderl S, Gandhi V, O’Brien S, et al. Clofarabine is active in myelodysplastic syndrome (MDS) [abstract].Blood 2006;108. Abstract 2660.
Aguayo A. The role of angiogenesis in the biology and therapy of myelodysplastic syndromes.Curr Hematol Rep. 2004;3:184–191.
Deeg HJ, Gotlib J, Beckham C, et al. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study.Leukemia. 2002;16:162–164.
Schiller GJ, Slack J, Hainsworth JD, et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. JClin Oncol. 2006;24:2456–2464.
About this article
Cite this article
Oki, Y., Issa, J.J. Treatment Options in Advanced Myelodysplastic Syndrome, with Emphasis on Epigenetic Therapy. Int J Hematol 86, 306–314 (2007). https://doi.org/10.1532/IJH97.07034
- Myelodysplastic syndrome
- Epigenetic therapy
- DNA methylation
- Histone deacetylase inhibitors